TargetMol

JWG-071

Product Code:
 
TAR-T14547
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T14547-50mg50mgEnquire
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T14547-1mg1mg£122.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T14547-5mg5mg£195.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T14547-10mg10mg£227.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T14547-1mL1 mL * 10 mM (in DMSO)£238.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T14547-25mg25mg£309.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
JWG-071 is the first reported kinase-selective chemical probe for ERK5. JWG-071 will be a much-needed chemical probe for deconvoluting ERK5 and BRD4 pharmacology[1]. JWG-071 improves ERK5 activity and BRD4 selectivity.
CAS:
2250323-50-1
Formula:
C34H44N8O3
Molecular Weight:
612.779
Pathway:
MAPK
Purity:
0.98
SMILES:
CCC(C)N1c2ccccc2C(=O)N(C)c2cnc(Nc3ccc(cc3OC)C(=O)N3CCC(CC3)N3CCN(C)CC3)nc12
Target:
ERK

References

1. Wang J, et al. Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinonesas Inhibitors of Kinases and Bromodomains. ACS Chem Biol. 2018 Sep 21;13(9):2438-2448